Published: Jan. 1, 2024
Background: COVID-19 has caused a great test to people's life safety, especially for the elderly group over 60 years old. Azvudine and Paxlovid were widely used as anti-COVID-19 drugs in clinical treatment during first Omicron wave China. Herein, we aimed compare efficacy safety of two population.Methods: In this retrospective study conducted at nine hospitals Henan Province, China, total 5131 hospitalized patients included from December 5, 2022, January 31, 2023. The main focus was on all-cause mortality composite disease progression. Comparative evaluations carried out between groups using Kaplan–Meier Cox regression methods. To ensure reliability results, subgroup sensitivity analyses employed.Results: Following exclusions propensity score matching, 1769 treated with 892 selected. analysis revealed had higher risk death (HR: 1.33, 95% CI: 1.066-1.663, p=0.01) versus group, but no difference progression 0.9, 0.752-1.082, p=0.26). Notably, compared without primary malignant tumors, exhibited 2.69, 1.39−5.21, p=0.037) tumors. robustness these findings confirmed through three analyses.Interpretation: results suggest that among have lower fewer adverse effects.Trial Registration: This also completed registration ClinicalTrials under clinicaltrial number NCT06349655. Funding: work supported by National Key Research Development Program China (2022YFC2303100 Z.R.). Province Epidemic Prevention Control Emergency Scientific Project (221111311700 Z.R.), Central Plains Talent Program-Central Youth Top Talents Z.R., Young Middleaged Academic Leaders Provincial Health Commission (HNSWJW-2022013 Innovation Team First Affiliated Hospital Zhengzhou University (QNCXTD2023002 Declaration Interest: authors declare conflict interestEthical Approval: endorsed research ethics committee AffiliatedHospital authorized approval 2023-KY0865-001.
Language: Английский